# Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster

> **NCT07640308** · PHASE1 · NOT_YET_RECRUITING · sponsor: **The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)** · enrollment: 90 (estimated)

## Conditions studied

- Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus)

## Interventions

- **BIOLOGICAL:** Grupo 1 - dose 25 μg
- **BIOLOGICAL:** Group 2 - 50 μg dose
- **BIOLOGICAL:** Group 3 - 100 μg

## Key facts

- **NCT ID:** NCT07640308
- **Lead sponsor:** The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-07
- **Final completion:** 2028-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640308, "Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*